[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-liver-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-liver-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,50,84,106,129,153,180,208,248,275,296],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640555","establishing-a-reference-framework-for-outcomes-after-machine-preserved-liver-transplantation-in-europe-100640555",false,"NCT07585890","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe","Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)","REFRAME-MP","Inclusion Criteria:\n\n* All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients \\>18 years at the time of liver transplantation.\n* All donor types (DBD, DCD)\n* Preservation either with static cold storage alone or combined with machine perfusion (MP).\n* Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice.\n* Eligible MP protocols are:\n\n  1. end-ischemic single- or dual hypothermic oxygenated MP \\[e(D)HOPE\\],\n  2. end-ischemic (back-to-base) normothermic MP \\[eNMP\\],\n  3. continuous (device-to-donor) normothermic MP \\[cNMP\\],\n  4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP \\[e(D)HOPE-COR-NMP)\\],\n  5. e(D)HOPE followed by normothermic MP \\[e(D)HOPE-NMP\\], or\n  6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol.\n* A minimum follow-up of 12 months after liver transplantation is required.\n\nExclusion Criteria:\n\n* Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention.\n* Living donor liver transplantation","ALL","18 Years",{"count":20,"type":21},10000,"ESTIMATED","OBSERVATIONAL","Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is a critical need for an updated reference framework that accurately reflects current clinical practice and captures the best achievable outcomes across all MP modalities.",[25,26,27,28],"End-stage Liver Disease (ESLD)","Acute Liver Failure","Liver Cirrhosis","Liver Transplantation",[30,31,32,33,34,35,36],"machine perfusion","liver transplantation","hypothermic machine perfusion","normothermic machine perfusion","normothermic regional perfusion","organ preservation","machine preservation","RECRUITING","2026-05-11",{"date":40,"type":41},"2026-05-14","ACTUAL",{"date":43,"type":41},"2026-04-21",{"date":45,"type":21},"2030-12-31",{"name":47,"class":48},"University Medical Center Groningen","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100428681","phase-2-treatment-for-immune-mediated-pathophysiology-100428681","NCT04862221","TReatment for ImmUne Mediated PathopHysiology","A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients","TRIUMPH","Inclusion Criteria:\n\n1. Patient with liver injury of ≤ 6 weeks duration resulting in an international normalization ratio (INR) of ≥ 1.5 or \\\u003C 2.0 (not corrected by vitamin K) with evidence of hepatic encephalopathy (HE), INR of ≥ 1.5 or \\\u003C 2.0 for at least 7 days duration without evidence of HE or INR ≥ 2.0 without evidence of HE.\n2. Age is greater than or equal to 1 year and less than 18 years of age.\n3. Patient or their legally authorized representative(s) (LAR) must consent (and assent, if applicable) to be in the study and must have signed and dated an approved informed consent form which conforms to federal and institutional guidelines.\n4. Females of reproductive potential should not plan on conceiving children during the study and must agree to use a medically accepted form of contraception.\n\nExclusion Criteria:\n\n1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes simplex virus (HSV) or adenovirus infection\n2. Travel within the past 3 months to an area highly endemic for Hepatitis E\n3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of consanguinity and\u002For central nervous system (CNS) dysfunction that is exaggerated compared to the degree of liver dysfunction (as judged by the site investigator) will not be enrolled until results of rapid genetic testing are available. Turn-around time for genetic testing results is estimated to be 72-96 hours.\n4. Aplastic anemia as defined by standardized criteria \\[1\\] diagnosed prior to enrollment\n5. Diagnosis of autoimmune Hepatitis (AIH)\n6. Diagnosis of acute Wilson disease\n7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an exclusion for entry into the Trial.\n8. Diagnosis of acute drug or toxin-induced liver injury\n9. History of recreational drug use within the past 4 weeks\n10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies or an experimental drug or device within the past 6 weeks\n11. Liver injury due to ischemia\n12. Liver dysfunction diagnosed more than 6 weeks prior to screening\n13. History of allergy to horse dander\n14. Sepsis\n15. Imminent risk of death as judged by the clinical site investigator, including but not limited to; signs of cerebral herniation at the time of enrollment and presence of intractable arterial hypotension\n16. Solid organ or stem cell transplant recipient\n17. Pregnant or breast-feeding at the time of proposed study entry\n18. Clinical AIDS or HIV positive\n19. History of any form of malignant neoplasm and\u002For tumors treated within five years prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer) or where there is current evidence of recurrent or metastatic disease\n20. Received a live-virus vaccine within 4 weeks of study entry\n21. Patients with positive respiratory secretion testing for respiratory viral infection including SARS-CoV-2, influenza and respiratory syncytial virus only if they also have declining respiratory function\n22. Psychiatric or addictive disorders that would preclude obtaining informed consent\u002Fassent\n23. Patient is unwilling or unable to adhere with study requirements and procedures\n24. Currently receiving other experimental therapies","1 Year",{"count":60,"type":21},163,"INTERVENTIONAL",[63],"PHASE2","TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.",[26,66,67,68,69],"Fulminant Hepatic Failure","Hepatic Encephalopathy","Acute Liver Injury","Immune Dysregulation",[71,72,73,74],"hepatic insufficiency","liver diseases","liver failure","anti-thymocyte agents",{"date":40,"type":41},{"date":77,"type":41},"2022-02-09",{"date":79,"type":21},"2027-02",{"name":81,"class":82},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",24,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":91,"targetDuration":93,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100635697","etiology-and-prognostic-factors-in-patients-with-acute-liver-failure-100635697","NCT07556055","Etiology and Prognostic Factors in Patients With Acute Liver Failure","A Bidirectional Cohort Study on the Etiology and Prognostic Factors of Acute Liver Failure and Development of a Dynamic Prediction Model","Inclusion Criteria:\n\n* Patients meeting diagnostic criteria for acute liver failure:\n\nAdults: Acute onset without pre-existing liver disease, development of hepatic encephalopathy ≥ grade II within 4 weeks Pediatrics: Acute onset (\\\u003C26 weeks), no chronic liver disease, coagulopathy not corrected by vitamin K: INR ≥1.5 with encephalopathy OR; INR \\>2 regardless of encephalopathy\n\n* Patients (or guardians) who provide informed consent\n\nExclusion Criteria:\n\n* Presence of end-stage extrahepatic disease without effective treatment\n* Pregnant or breastfeeding women\n* Inability or unwillingness to provide informed consent or comply with study procedures",{"count":92,"type":21},400,"3 Years","Acute liver failure (ALF) is a rare but life-threatening condition with high mortality. Despite advances in supportive care and liver transplantation, prognosis varies significantly across etiologies, particularly in patients with indeterminate causes.\n\nThis study aims to investigate the dynamic changes of clinical and biochemical indicators, identify potential etiologies-especially in indeterminate ALF-and evaluate prognostic risk factors. A dynamic prediction model will be developed to optimize clinical decision-making, including liver transplantation timing.\n\nBoth retrospective and prospective cohorts will be included. Multi-omics analyses (including transcriptomics, proteomics, metabolomics, and metagenomic sequencing) will be performed on liver tissue and biological samples to explore disease mechanisms and etiology.",[26],"NOT_YET_RECRUITING","2026-04-22",{"date":99,"type":41},"2026-04-29",{"date":101,"type":21},"2026-03-30",{"date":103,"type":21},"2037-12-31",{"name":105,"class":48},"Li-Ying Sun",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":18,"enrollmentInfo":113,"targetDuration":4,"studyType":61,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100580003","standard-volume-vs-high-volume-plasma-exchange-in-pediatric-acute-liver-failure-100580003","NCT06831643","Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure","Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure - A Pilot Randomized Control Trial","Inclusion Criteria:\n\n1. Age: 3 years to 18 years\n2. Fulfilling PALFSG definition (J Pediatr. 2006 May;148(5):652-658).\n3. Baseline INR ≥ 2.5, and increasing INR (any value) and\u002For worsening hepatic. encephalopathy (\\> 1 grade change) after 6 to 12 hours of standard medical therapy.\n\nExclusion Criteria:\n\n1. Disseminated intravascular coagulation\n2. Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine \\>0.5 mcg\u002Fkg\u002Fmin)\n3. Signs of irreversible brain injury\n4. Any severe cardio-pulmonary pre-existing disease\n5. Septic Shock",{"count":114,"type":21},40,[116],"NA","Acute liver failure is a multisystem disorder characterized by a syndrome of jaundice, coagulopathy, and encephalopathy with high mortality in the absence of liver transplantation. The pathogenesis of multiorgan failure (MOF) in ALF has been attributed to the release of damage-associated molecular patterns (DAMPs) from injured hepatic cells and microbial pathogen-associated molecular patterns (PAMPs) in the presence of superimposed infection or bacterial translocation.The innate immune cells activated by PAMPs and DAMPs produce pro-inflammatory cytokines \\[interleukin (IL)-6, IL-1b, IL-8, tumor necrosis factor-alpha (TNF-a)\\]. Studies indicate that the removal of inflammatory mediators appears to play a role in the treatment of ALF and are removed by some apheresis techniques. Hence therapeutic exchange (TPE) has been used as adjunct or standalone therapy for bridging patients to recovery or LT. TPE to treat liver failure involves two steps-removal of plasma from a patient with liver failure and replacing this with equal volume of fluid; in view of the coagulopathy seen in liver failure patients, the preferred fluid for replacement is fresh frozen plasma. Different doses of PLEX have been used to treat liver failure patients with high, standard or low volume PLEX, to treat ALF. Presently American Apheresis Society guidelines consider High Volume TPE (HV-TPE) as first line the management of ALF. But HV-TPE, apart from strain on blood bank resources (large volumes of fresh frozen plasma needed), also carries risk of transfusion associated acute lung complications, risk of blood borne virus infection, and so on make the use of low-volume PLEX attractive compared to high-volume PLEX. Hence this study is being carried out to consider the safety and efficacy of standard volume plasma exchange (SV-TPE) vs. HV-TPE in Pediatric ALF.",[26],"2025-12-31",{"date":121,"type":41},"2026-01-06",{"date":123,"type":41},"2025-02-17",{"date":125,"type":21},"2026-12-31",{"name":127,"class":48},"Institute of Liver and Biliary Sciences, India",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":61,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":128},"100618239","alss---dpmas-and-therapeutic-plasma-exchange-tpe-its-effect-on-primary-coagulation-inflammation-and-the-function-of-vital-organs-in-alf-or-aclf-100618239","NCT07329036","ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF","The Artificial Liver Support System (ALSS) in Patients With Acute on Chronic Liver Failure - the Use of Combined Molecular Adsorption System With Double Plasma (DPMAS) and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation and the Function of Vital Organs.","Inclusion Criteria:\n\n* Adult patient, age ≥18 years\n* Expressed consent to the inclusion\n* Patient hospitalized on ICU with ALF or ACLF diagnosis\n* Recently meeting the inclusion to liver transplantation\n* Present on a waiting list to liver transplant\n* Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care\n\nExclusion Criteria:\n\n* Disagreement with the study\n* Infaust prognosis with expected survival less than 24 hours\n* Physiologically\u002Fbiologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.\n* Advanced oncological disease (expected life expectancy below 6 months)\n* Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according","75 Years",{"count":138,"type":21},25,[116],"The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.",[26],[143],"acute liver failure","2025-12-28",{"date":146,"type":41},"2026-01-09",{"date":148,"type":41},"2024-04-01",{"date":125,"type":21},{"name":151,"class":152},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":61,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":179},"100492246","phase-2-f573-for-injection-for-the-treatment-of-liver-injuryfailure-100492246","NCT05689645","F573 for Injection for the Treatment of Liver Injury\u002FFailure","F573 for Injection for the Treatment of Liver Injury\u002FFailure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical Trial","Inclusion Criteria:\n\n（1）The first stage:\n\nParticipants who meet all of the following criteria will be enrolled in the study:\n\n1. Age ≥18 and ≤60 years old, gender is not limited;\n2. Patients with liver injury clinically diagnosed with hepatocyte injury or mixed liver injury or CHB patients with hepatitis B virus infection for more than 6 months (refer to the \"Chronic Hepatitis B Prevention and Treatment Guidelines (2019 edition)\"). Screening patients with CHB may provide etiological (HBsAg positive and\u002For HBV DNA positive) or clinical or pathological evidence (liver tissue biopsy results) that HBV infection has been present for more than 6 months.\n3. Serum ALT: 2\\~ 10× upper limit of normal (ULN), TBil: \\\u003C5×ULN;\n4. DILI patients: the abnormal duration of liver biochemical indexes \\[ALT, AST, ALP, gamma-glutamyltranspeptides (GGT), TBil, albumin, prothrombin time\\] does not exceed 90 days;\n5. The subject (including the partner) is willing to take effective contraceptive measures from the screening until 6 months after the last test drug administration;\n6. Sign informed consent and be able to comply with the requirements of the program; If the subject is unable to sign the informed consent form, it must be signed by a legal guardian or witness as required by the regulations.\n\n(2)The second stage:\n\nSubjects meeting all of the following criteria will be included in the study:\n\n1. Age ≥ 18 and ≤ 65 years old, with no gender restrictions;\n2. According to the \"Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury (2023 Edition)\", patients diagnosed with drug-induced liver injury (DILI) or those diagnosed with intrahepatic cholestasis type liver injury. Patients with DILI and intrahepatic cholestasis type liver injury need to meet the following criteria separately;\n\n   1. Patients with DILI need to simultaneously meet the following conditions: ① Serum ALT \\> 3 times the upper limit of normal (ULN), and TBil \\> 2 times the ULN (the ULN of TBil refers to 17.1 μmol\u002FL according to international standards); ② Abnormal liver biochemical indicators (ALT, AST, ALP, TBil) persist for no more than 60 days;\n   2. Patients with intrahepatic cholestasis type liver injury need to simultaneously meet the following conditions: ① TBil \\> 2 times the ULN (the ULN of TBil refers to 17.1 μmol\u002FL); ② ALP \\> 1.5 times the ULN; ③ALT\\>1×ULN;\n3. The subjects (including their partners) are willing to voluntarily adopt effective contraceptive measures from the time of the initial screening until 6 months after the last administration of the investigational drug;\n4. They have signed the informed consent form and can comply with the requirements of the protocol; if the subjects are unable to sign the informed consent form, it must be signed by a legal guardian or a witness as required by the regulations.\n\nThe third stage:\n\nSubjects who meet all of the following criteria will be enrolled in the study:\n\n1\\. Age ≥18 and ≤70 years old, gender is not limited; 2. Patients diagnosed with chronic and acute liver failure with TBil≥5×ULN according to the \"Guidelines for Diagnosis and Treatment of Liver Failure (2018 Edition)\" may have hepatic encephalopathy (Grade 1-2) or ascites (grade 1-2) 4 weeks before subject screening. And 5≤AARC score ≤10 (AARC rating I-II); 3. The subject (including the partner) is willing to take effective contraceptive measures from the screening until 6 months after the last trial drug administration; 4. Sign informed consent and comply with the requirements of the program; If the subject is unable to sign the informed consent form, it must be signed by a legal guardian or witness as required by the regulations.\n\n\\-\n\nExclusion Criteria:\n\nThe first stage:\n\nSubjects meeting one of the following conditions will not be included in the trial:\n\n1. According to the investigator's judgment, the subjects were patients with cholestatic liver injury;\n2. Previous diagnosis of cirrhosis or liver hardness determination (LSM) at screening ≥ 12.4kPa;\n3. Patients with severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases, and patients with malignant tumors;\n4. There are the following laboratory test values or abnormal test values:\n\n   1. Blood routine: platelet (PLT) \\\u003C75× 109\u002FL, hemoglobin (HGB) \\\u003C90 g\u002FL;\n   2. Prothrombin activity \\\u003C40%, prothrombin time (PT) extended \\>5 s;\n   3. Left ventricular ejection fraction (LVEF) \\\u003C50%;\n5. Allergic or intolerant to the investigational drug, or allergic;\n6. The subject is unable to express his main complaint, such as mental illness and severe neurosis;\n7. Poor compliance can not partner;\n8. Pregnant women, breastfeeding women or women of childbearing age who are trying to conceive;\n9. Participants in other clinical trials within 3 months;\n10. Patients who had used liver protection drugs other than ursodeoxycholic acid or adenosylmethionine within 3 days before randomization;\n11. The researcher considers any circumstances unsuitable for inclusion.\n\nThe second stage:\n\nSubjects meeting one of the following conditions will not be included in the trial:\n\n1. The diagnosis is advanced liver cirrhosis (with complications such as ascites and hepatic encephalopathy), or liver cancer, or when liver stiffness measurement (LSM) is ≥ 18.0 kPa during screening.\n2. Patients with severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases are malignantTumor patients;\n3. There are the following laboratory test values or abnormal test values:\n\n   1. Blood routine: platelet (PLT) \\\u003C100×109\u002FL, hemoglobin (HGB) \\\u003C100 g\u002FL;\n   2. INR\\>1.4, or as determined by the investigator to meet the criteria for severe hepatitis;\n   3. Left ventricular ejection fraction (LVEF) \\\u003C50%;\n4. Allergic or intolerant to the investigational drug, or allergic;\n5. The subject is unable to express his main complaint, such as mental illness and severe neurosis;\n6. Poor compliance can not partner;\n7. Pregnant women, breastfeeding women or women of childbearing age who are trying to conceive;\n8. Participants in other clinical trials within 3 months;\n9. Patients who had used liver protection drugs other than ursodeoxycholic acid or adenosylmethionine and basic therapeutic drugs (polyene phosphatidylcholines and glutathione drugs) within 3 days before randomization;\n10. Patients who had used glucocorticoids or interferon drugs within 3 days before randomization;\n11. The researcher considers any circumstances unsuitable for inclusion.\n\nThe third stage:\n\nSubjects meeting one of the following conditions will not be included in the trial:\n\n1. Patients who have completed liver transplantation or plan to undergo liver transplantation within 1 month;\n2. Severe grade 3 ascites or stubborn ascites;\n3. Patients with ≥ grade 3 hepatic encephalopathy;\n4. Patients who received artificial liver treatment within 1 week before screening;\n5. Patients with severe underlying diseases, such as respiratory system, digestive system, circulatory system, endocrine and other diseases and malignant tumors, and patients with severe infections that cannot be controlled by drugs;\n6. During the screening period or within 1 month before screening, the results of gastroscopy or imaging (abdominal B-ultrasound, CT or MRI) examination suggest severe varicose veins with bleeding risk;\n7. Patients with acute kidney injury (AKI), defined as meeting one of the following conditions:\n\n   1. Serum creatinine (Scr) increased ≥26.5 μmol\u002FL (0.3 mg\u002FdL, 1 mg\u002FdL=88.4 μmol\u002FL) within 48 h;\n   2. The Scr increase exceeds 1.5 times or more of the base value within 7 days;\n   3. Decreased urine volume (\\\u003C0.5 mL\u002Fkg\u002Fh) for more than 6 hours;\n8. Allergic or intolerant to the investigational drug, or allergic;\n9. The subject is unable to express his main complaint, such as mental illness and severe neurosis;\n10. Poor compliance can not partner; 11 Pregnant women, breastfeeding women or women of childbearing age who are trying to conceive;\n\n12\\. Participants in other clinical trials within 3 months; 13. The researcher considers any circumstances unsuitable for inclusion.","60 Years",{"count":162,"type":21},97,[63],"This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial .\n\nThe primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).",[26,166],"Acute-On-Chronic Liver Failure",[168],"F573 for injection Liver Injury\u002FFailure","2025-11-17",{"date":171,"type":41},"2025-11-19",{"date":173,"type":41},"2023-03-24",{"date":175,"type":21},"2026-09-01",{"name":177,"class":178},"Beijing Continent Pharmaceutical Co, Ltd.","INDUSTRY",10,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":61,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":128},"100555673","high-volume-versus-standard-volume-plasma-exchange-in-patients-with-acute-liver-failure-with-cerebral-edema-100555673","NCT06515145","High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema","To Evaluate the Safety and Efficacy of High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema -A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\nPatients with acute liver failure defined as patients with jaundice which is complicated by encephalopathy and coagulopathy within 4 weeks of the onset of jaundice and without underlying chronic liver disease.\n\nCerebral edema documented on CT-scan and arterial ammonia \\>150 ug\u002FdL\n\nExclusion Criteria:\n\n1. Age \\\u003C18 or \\> 70 years\n2. HCC\n3. Active untreated Sepsis\u002FDIC\n4. Hemodynamic instability non-responsive to initial fluid resuscitation with norepinephrine \\>0.1 ug\u002Fkg\u002Fmin\n5. Post-resection and malignancy related liver failure\n6. Coma of non-hepatic origin\n7. Patients with uncontrolled infection\n8. Patients with pulmonary involvement with Pa02\u002FFio2 ratio below 200.\n9. Patients with post renal obstructive AKI, AKI suspected due to glomerulonephritis, interstitial nephritis or vasculitis based on clinical history and urine analysis\n10. Extremely moribund patients with an expected life expectancy of less than 24 hours\n11. Pregnancy related liver failure\n12. Comorbidities associated with poor outcome (Extrahepatic neoplasia, severe cardiopulmonary disease defined by a New York Heart Association score \\>3, or oxygen\u002Fsteroid-dependent chronic obstructive pulmonary disease)\n13. Refusal to participate in the study\n14. Drug-induced ALF","70 Years",{"count":189,"type":21},60,[116],"In this prospective randomized controlled trial Investigator aim to evaluate the impact of high versus standard volume plasma-exchange in patients with acute liver failure with cerebral edema and clinical outcomes. ALF who meet the inclusion and exclusion criteria within the first 12 hours will be randomized into two groups\n\nInterventional - High-volume plasma exchange Active Comparator - Standard volume plasma exchange\n\nExpected outcome of the project-.\n\n1. Primary end points: Time to improvement in cerebral edema\n2. Secondary end points:\n\nTo study the adverse events of therapy (volume overload, pulmonary complications, allergic reactions) etc.\n\nTransplant-free survival at day 21",[26,193],"Cerebral Edema",[195,196,197,198,199],"Plasma-exchange","systemic inflammatory response syndrome","lactate","CRRT","sepsis","2025-09-18",{"date":202,"type":41},"2025-09-19",{"date":204,"type":21},"2025-12-01",{"date":206,"type":21},"2026-03-01",{"name":127,"class":48},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":22,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":247},"100450503","cytosorb-treatment-of-critically-ill-patients-registry-100450503","NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.",{"count":217,"type":21},3000,"3 Months","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[221,222,223,224,225,226,227,26,228,229,230,231,232,233,234,235,236,237],"Septic Shock","Acute Respiratory Distress Syndrome","Trauma","Rhabdomyolysis","Cardiogenic Shock","Pancreatitis","Acute on Chronic Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Hemophagocytic Lymphohistiocytoses","Liver Transplant; Complications","Infectious Disease","Postoperative Vasoplegic Syndrome","Drug Overdose","Sepsis","2025-09-10",{"date":240,"type":41},"2025-09-11",{"date":242,"type":41},"2022-06-22",{"date":244,"type":21},"2032-09",{"name":246,"class":178},"CytoSorbents, Inc",28,{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100603088","transcriptional-analysis-of-mechanisms-in-liver-failure-and-sepsis-100603088","NCT07131969","Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis","Transcriptional Analysis of Mechanisms and Predictors in Acute Liver Failure and Sepsis","MAP-ALF","Inclusion Criteria:\n\n* acute liver failure due to acetaminophen (paracetamol) overdose admitted to ICU\n* all cause sepsis admitted to ICU\n\nExclusion Criteria:\n\n* age \\\u003C16y",{"count":257,"type":21},100,"Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure.\n\nChallenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.\n\nAim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.\n\nImportance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.",[26,237],[143,199,261,262,263,264],"transcriptional analysis","predictors","paracetamol overdose","acetaminophen overdose","2025-08-19",{"date":267,"type":41},"2025-08-26",{"date":269,"type":21},"2025-09",{"date":271,"type":21},"2028-09",{"name":273,"class":48},"University of Cambridge",7,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":283,"maxAge":18,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100575950","etiology-and-prognostic-analysis-of-acute-liver-failure-in-chinese-children-100575950","NCT06778941","Etiology and Prognostic Analysis of Acute Liver Failure in Chinese Children","Etiology and Prognostic Analysis of Acute Liver Failure in Chinese Children: a Multi-center Bidirectional Observational Cohort Study","EPOCH-ALF","Inclusion Criteria:\n\n1. According to the diagnostic criteria for PALF, the following conditions must be met:\n\n   ① Severe biochemical liver abnormalities occurring within 8 weeks;\n\n   ② Coagulation disorders uncorrectable by vitamin K: if hepatic encephalopathy is present, prothrombin time (PT) \\> 15s or international normalized ratio (INR) \\> 1.5; regardless of the presence of hepatic encephalopathy, PT \\> 20s or INR \\> 2.0.\n2. For patients who were admitted twice, only the information from the first hospitalization will be used.\n3. Patients with a history of chronic liver disease (e.g., genetic metabolic factors, drug-induced factors) or biliary obstruction that led to the acute episode are categorized under acute liver failure.\n4. The child's legal guardian has signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Age \\> 18 years;\n2. Significant data missing (\\>10%);\n3. The child's legal guardian refuses participation.","28 Days",{"count":92,"type":21},"Research Background:\n\nPediatric acute liver failure (PALF) refers to the sudden onset of severe liver injury in children without known chronic liver disease, leading to multi-system organ dysfunction, with a mortality rate as high as 50%-70%. The etiology of PALF is complex and varied, including infections, metabolic disorders, and toxins. In developed countries, it is often caused by drug and toxin exposure, while in developing countries, viral infections are the primary cause. Additionally, 30%-50% of PALF cases have an unknown etiology, which increases the difficulty of treatment. Current treatment options include medical management, artificial liver support, and liver transplantation. Liver transplantation is the only proven effective treatment, but issues such as organ shortages and the timing of transplantation affect treatment outcomes. Improving diagnostic capabilities for the etiology and exploring optimal treatment strategies are of significant importance in enhancing the clinical success rate of PALF management.\n\nResearch Objective:\n\nTo explore the etiology and prognostic factors of pediatric acute liver failure (PALF), analyze the relationship between different causes of PALF and prognosis, and the relationship between different treatment modalities and prognosis. This study aims to investigate the correlation between etiology, treatment methods, and outcomes, providing scientific evidence to improve the precision in diagnosis and treatment of PALF and to enhance decision-making and timing judgments for liver transplantation.",[26],"2025-01-12",{"date":289,"type":41},"2025-01-16",{"date":291,"type":21},"2025-02-01",{"date":293,"type":21},"2029-06-30",{"name":295,"class":48},"liyumei",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":18,"enrollmentInfo":303,"targetDuration":4,"studyType":61,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":128},"100569803","daily-versus-alternate-day-plasma-exchange-in-wilson-disease-with-acute-liver-failure-in-children-100569803","NCT06698991","Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children","Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Wilson disease with New Wilson Index of ≥ 11 and INR ≥ 2.5\n2. Children aged 3 years to 18 years\n\nExclusion Criteria:\n\n1. Grade 3 or grade 4 hepatic encephalopathy\n2. Septic shock\n3. Disseminated intravascular coagulation\n4. Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine \\>0.5 mcg\u002Fkg\u002Fmin)\n5. Any severe cardio-pulmonary pre-existing disease",{"count":304,"type":21},20,[116],"Wilson disease in children has a varied presentation. Wilson disease with acute liver failure is associated with very high mortality and morbidity. The standard therapy i.e chelation (with either D- penicillamine or trientene can be used as a temporizing agent to treat the enormous release of copper into the blood stream; however, substantial removal is not achieved for at least 1 to 3 months. Plasma exchange provides a means of rapid means of removal of copper. As per American Society for Apheresis, TPE in wilson disease with acute liver failure can rapidly remove an average of 20 mg of copper per TPE treatment. Decreased serum copper may decrease hemolysis, prevent progression of kidney failure and provide clinical stabilization. TPE can also remove large molecular weight toxins (aromatic amino acids, ammonia, endotoxins) and other factors, which may be responsible for hepatic coma. The frequency of said TPE is not defined as most evidence is based on case reports and case series.\n\nCopper is highly protein bound and the volume of distribution for copper is large. Under normal conditions, 90-95% of serum copper is ceruloplasmin-bound with the remaining 5-10% being nonceruloplasmin-bound. TPE efficiently removes both ceruloplasmin- and albumin-bound copper. FFP used for exchange can be helpful in treating the associated coagulopathy. TPE has been used as a bridge to liver transplantation as well as seen to improve survival with native liver, the optimum protocol for same remains uncertain.",[26,308],"Wilson Disease","2024-11-19",{"date":311,"type":41},"2024-11-21",{"date":313,"type":21},"2024-11-10",{"date":125,"type":21},{"name":127,"class":48}]